Biotech Startups

Chunk Foods makes plant-based meat alternatives produced through fermentation, including a whole-cut product designed for slicing, slow-cooking, marinating, and roasting. The products use Non-GMO, clean-label ingredients and are high in protein and fiber.

7 investors

Coding Bio develops modular immunotherapies for cancer patients, using a high-throughput lab to screen millions of protein candidates in living cells and a machine learning platform to design and optimize therapies for immune activation. The company operates in the immuno-oncology and cell therapy space, aiming to accelerate development of CAR and related therapies.

7 investors

Concert Bio uses DNA sequencing and a microbiome database to identify pathogens and beneficial microbes, then supplies beneficial microbes to hydroponic greenhouse growers to improve crop growth, quality, and yield. It serves hydroponic growers as an agtech platform for optimizing the plant microbiome.

7 investors

Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured. Its platform aims to move novel molecules from research to industrial-scale production for applications ranging from medicines to advanced materials.

7 investors

Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity. The company operates in the biotech and drug development sector.

7 investors

CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.

7 investors

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases. It operates in clinical-stage vaccine development.

7 investors

Deep Genomics develops AI-based biological foundation models to identify drug targets and design molecules, aiming to speed up drug discovery. Its platform combines lab-in-the-loop workflows, training datasets, and screening technologies to find candidates for developing new medicines.

7 investors

Deepcell uses artificial intelligence and high-resolution imaging to analyze cell morphology for biological research and discovery. The company serves scientists and life science researchers across multiple biological domains.

7 investors

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases. Its DIAGONAL Product Engine uses computational and experimental methods to identify clustering antibodies across receptor classes, with a lead candidate (DIAG723) in a Phase 1/2 trial for Hereditary Hemorrhagic Telangiectasia.

7 investors

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need. It is led by a team of scientists and industry veterans across chemistry, clinical development, and medical affairs.

7 investors

DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis. It serves biomedical organizations including pharmaceutical companies, clinical diagnostics providers, academic medical centers, and biobanks, with built-in GxP and regulatory compliance.

7 investors

Dyno Therapeutics develops artificial intelligence-powered genetic technologies for gene therapy, specifically engineering adeno-associated virus (AAV) capsids to improve gene delivery for treating genetic diseases. The company works with pharmaceutical partners including Novartis, Sarepta, Roche, Spark, and Astellas to advance therapies for patients with genetic disorders.

7 investors

eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.

7 investors

Elypta develops a metabolism-based liquid biopsy that measures the GAGome, a set of biomarkers of tumor metabolism, and applies machine learning to noninvasively detect cancer signatures. The company focuses on early cancer detection to reduce cancer mortality.

7 investors

Emulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research. It serves life sciences and pharmaceutical researchers and provides installation, training, and validated protocols for Organ-Chip experiments.

7 investors

Encoded develops gene therapies for neurological disorders through an integrated platform approach. The company focuses on translating discoveries from research through clinical development and commercialization.

7 investors

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment. Its technology aims to selectively and durably modify cells of the hematopoietic system for patients.

7 investors

Epana Bio develops therapies for autoimmune diseases by leveraging genomics and AI to identify and target cellular origins of disease, with a focus on precision medicine for patient populations.

7 investors

Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.

7 investors

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective. The company operates an early access program to provide investigational therapies to qualified patients with life-threatening fungal infections who are ineligible for clinical trials or lack suitable alternative treatment options.

7 investors

FairCraft develops lab-grown leather produced from cells and proteins through a material discovery platform, offering an animal-free alternative with low environmental impact. The company creates cell-based materials that brands can fine-tune for touch, feel, and transformability properties.

7 investors

Filtricine is a clinical-stage biotechnology company developing nutrition-based medical food products for disease control, using its Targeted Nutrients Deprivation (TND) approach to starve cancer cells while providing balanced nutrition to patients. Its focus is on "food as medicine" interventions for cancer and other common diseases.

7 investors

FinalDose develops a programmable DNA-targeting molecule designed to recognize and destroy cells carrying specific genetic sequences, with initial applications in oncology across cancer types.

7 investors